Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22214
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNaka, K. K.en
dc.contributor.authorKalantaridou, S. N.en
dc.contributor.authorBechlioulis, A.en
dc.contributor.authorKravariti, M.en
dc.contributor.authorKazakos, N.en
dc.contributor.authorKatsouras, C. S.en
dc.contributor.authorTsatsoulis, A.en
dc.contributor.authorMichalis, L. K.en
dc.date.accessioned2015-11-24T19:22:57Z-
dc.date.available2015-11-24T19:22:57Z-
dc.identifier.issn1473-0766-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22214-
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAndrogen Antagonists/pharmacology/*therapeutic useen
dc.subjectCyproterone Acetate/pharmacology/*therapeutic useen
dc.subjectDrug Therapy, Combinationen
dc.subjectEstrogens/pharmacology/*therapeutic useen
dc.subjectEthinyl Estradiol/pharmacology/*therapeutic useen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectPilot Projectsen
dc.subjectPolycystic Ovary Syndrome/*drug therapyen
dc.subjectProspective Studiesen
dc.subjectRegression Analysisen
dc.subjectVasodilation/*drug effectsen
dc.subjectYoung Adulten
dc.titleEffect of ethinylestradiol/cyproterone acetate on endothelial function in young non-obese women with polycystic ovary syndrome: a pilot studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.3109/09513590.2010.521265-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21329419-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.3109/09513590.2010.521265-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2011-
heal.abstractBACKGROUND: Combined oral contraceptives are used in polycystic ovary syndrome (PCOS) women for the treatment of hyperandrogenism and menstrual cycle disturbances. AIM: To assess the effect of ethinylestradiol and cyproterone acetate (EE/CA) on endothelial function in young, non-obese PCOS women in a pilot study. METHODS: Thirteen young, non-obese PCOS women (20.9 +/- 3.7 years, 23.0 +/- 4.0 kg/m(2)) received 35 mcg EE & 2 mg CA for 6 months. Fourteen age- and body mass index (BMI)-matched healthy women served as controls. Endothelial function assessed by brachial artery flow-mediated dilation (FMD), indices of hyperandrogenism, and insulin resistance were studied at baseline and 6-month follow-up. RESULTS: FMD was impaired in PCOS compared to control women (4.67 +/- 2.38% vs. 10.12 +/- 3.19%, p < 0.001), but increased significantly following EE/CA (9.99 +/- 2.11%, p < 0.001 vs. baseline), reaching normal values (p = NS vs. controls). EE/CA also significantly decreased hyperandrogenism indices and increased total and HDL cholesterol and triglycerides (p < 0.05 vs. baseline). The only independent predictor of treatment-induced FMD improvement in PCOS women was the decrease in free androgen index. CONCLUSIONS: Treatment with combination of estrogens and antiandrogens reverses endothelial dysfunction in young, non-obese PCOS women mainly via improving hyperandrogenism. Further research is needed to investigate whether this treatment may also reduce cardiovascular risk in these women.en
heal.journalNameGynecol Endocrinolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons